追寻灵丹妙药：免疫治疗的黄金时代。
In search of magic bullets: the golden age of immunotherapeutics.
机构信息
Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
出版信息
Cell. 2014 Mar 27;157(1):227-40. doi: 10.1016/j.cell.2014.03.010.
Once upon a time, immunology was a black box, inflammatory and autoimmune diseases were a mystery, and relatively blunt tools were used to treat these diseases. In the last 40 years, advances in molecular biology, DNA recombination technology, and genome sequencing allowed immunologists to open the box. As the complexity and diversity of the immune response are unveiled, targeted cellular and molecular therapies now offer rational approaches to treat immune-mediated diseases. Here, we discuss how the tried and true bench-to-bedside strategies resulted in some spectacular successes, along with some puzzling failures. Conversely, the advent of targeted therapies in the clinic has led to a wealth of information that changes how we think about the pathogenesis of immune-mediated diseases and how we categorize disease. In turn, these insights can inform next-generation drug discovery and refine targeted therapies for the appropriate patient subsets.
曾几何时，免疫学是一个黑箱，炎症和自身免疫性疾病是一个谜，而且相对来说，治疗这些疾病的工具比较粗糙。在过去的 40 年中，分子生物学、DNA 重组技术和基因组测序的进步使免疫学家能够打开这个黑箱。随着免疫反应的复杂性和多样性逐渐被揭示，针对细胞和分子的治疗方法现在为治疗免疫介导的疾病提供了合理的方法。在这里，我们讨论了经过验证的从实验室到临床的策略是如何取得一些显著成功的，以及一些令人困惑的失败。相反，靶向治疗在临床上的出现带来了大量信息，这些信息改变了我们对免疫介导性疾病发病机制的看法，以及我们对疾病的分类方式。反过来，这些见解可以为下一代药物发现提供信息，并为合适的患者群体完善靶向治疗。
Zotero 插件